Akoustis Technologies Ord Shs
AKTS18.980USD
-0.590-3.01%
終値 02/06, 16:00（ET）15分遅れの株価
2.93B時価総額
損失額直近12ヶ月PER
詳細情報 Akoustis Technologies Ord Shs 企業名
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
Akoustis Technologies Ord Shsの企業情報
企業コードAKTS
会社名Aktis Oncology Inc
上場日Jan 09, 2026
最高経営責任者「CEO」Roden (Matthew)
従業員数117
証券種類Ordinary Share
決算期末Jan 09
本社所在地17 Drydock Avenue
都市BOSTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02210
電話番号13026587581
ウェブサイトhttps://www.aktisoncology.com/
企業コードAKTS
上場日Jan 09, 2026
最高経営責任者「CEO」Roden (Matthew)
Akoustis Technologies Ord Shsの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
+91998.00%
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
+2103.00%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Ms. Jill K. Frizzley
Ms. Jill K. Frizzley
Independent Director
Independent Director
--
--
Mr. Matthew R. Kahn, CPA
Mr. Matthew R. Kahn, CPA
Independent Director
Independent Director
--
--
Ms. Shulamit Ron-Bigger, Ph.D.
Ms. Shulamit Ron-Bigger, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Kyle D. Kuvalanka
Mr. Kyle D. Kuvalanka
Chief Financial Officer
Chief Financial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew (Matt) Roden, Ph.D.
Mr. Matthew (Matt) Roden, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.00K
+91998.00%
Mr. Todd Foley
Mr. Todd Foley
Chairman of the Board of Director
Chairman of the Board of Director
2.10K
+2103.00%
Mr. Arthur E. Geiss, Ph.D.
Mr. Arthur E. Geiss, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Dr. Jerry D. Neal, Ph.D.
Dr. Jerry D. Neal, Ph.D.
Independent Co-Chairman of the Board
Independent Co-Chairman of the Board
--
--
Mr. Paul L. Feldman, Ph.D.
Mr. Paul L. Feldman, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Tyler Benedum, Ph.D.
Mr. Tyler Benedum, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
収益内訳
通貨: USD更新時刻: Sat, Jan 10
通貨: USD更新時刻: Sat, Jan 10
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
Asia
5.84M
64.74%
Americas
2.43M
26.95%
Europe
750.00K
8.31%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Thu, Feb 5
更新時刻: Thu, Feb 5
株主統計
種類
株主統計
株主統計
比率
MPM BioImpact LLC
20.26%
Eli Lilly and Company
12.53%
VV Manager LLC
11.51%
EcoR1 Capital, LLC
9.53%
Feldman (Paul L. Ph.D.)
0.23%
他の
45.95%
株主統計
株主統計
比率
MPM BioImpact LLC
20.26%
Eli Lilly and Company
12.53%
VV Manager LLC
11.51%
EcoR1 Capital, LLC
9.53%
Feldman (Paul L. Ph.D.)
0.23%
他の
45.95%
種類
株主統計
比率
Investment Advisor/Hedge Fund
29.78%
Corporation
12.53%
Venture Capital
11.51%
Individual Investor
0.42%
他の
45.76%
機関投資家保有株
更新時刻: Sat, Jan 10
更新時刻: Sat, Jan 10
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
177
54.73K
0.04%
-32.32M
2025Q4
188
74.33K
0.05%
-32.41M
2025Q3
209
74.33K
0.05%
-35.90M
2025Q2
236
74.33K
0.05%
-41.95M
2025Q1
251
315.89K
0.20%
-42.44M
2024Q4
266
839.61K
0.54%
-43.07M
2024Q3
283
21.16M
13.70%
-24.03M
2024Q2
288
25.38M
23.18%
-30.85M
2024Q1
283
43.24M
43.52%
-1.29M
2023Q4
287
31.11M
40.06%
-14.76M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
データなし
詳細を見る
関連ETF
更新時刻: Sat, Jan 10
更新時刻: Sat, Jan 10
銘柄名
比率
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
iShares Micro-Cap ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
iShares Russell 2000 ETF
比率0%
iShares Russell 3000 ETF
比率0%
Global X Russell 2000 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
Proshares Ultra Russell 2000
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
